WO2000027377A2 - Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungen - Google Patents
Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungen Download PDFInfo
- Publication number
- WO2000027377A2 WO2000027377A2 PCT/EP1999/008181 EP9908181W WO0027377A2 WO 2000027377 A2 WO2000027377 A2 WO 2000027377A2 EP 9908181 W EP9908181 W EP 9908181W WO 0027377 A2 WO0027377 A2 WO 0027377A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pcp
- acid
- astacin
- phosphinate
- treatment
- Prior art date
Links
- 0 CC(C)CC(C(OC)=O)NC(C(CCC1)N1C(C(*)CP(C(Cc1ccccc1)NC(C(CCCCN)NC(C(CCC1)N1C(OCc1ccccc1)=O)=O)=O)(O)=O)=O)=O Chemical compound CC(C)CC(C(OC)=O)NC(C(CCC1)N1C(C(*)CP(C(Cc1ccccc1)NC(C(CCCCN)NC(C(CCC1)N1C(OCc1ccccc1)=O)=O)=O)(O)=O)=O)=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- Phosphinate peptide analogues for the treatment of fibrotic diseases are Phosphinate peptide analogues for the treatment of fibrotic diseases.
- the invention relates to the use of phosphinate peptide analogs as inhibitors of procollagen C proteinase (PCP) for the treatment of fibrotic diseases.
- PCP procollagen C proteinase
- PCP Procollagen C proteinase
- PCP is probably also responsible for the hydrolytic cleavage of the propeptide sequence of the lysyl oxidase.
- the cleavage of the prosequence probably leads to the activation of the catalytic lysyl oxidase activity of the matures
- PCP-like proteases can release TGFß-like growth factors from an inactive complex with TGFß binding proteins [cf. Marques G, Musacchio M, Shimell MJ, Wünnenberg-Stapleton K, Cho KWY, O'Connor MB: Production of a DPP activity gradient in the early drosophila embryo through the opposing actions of the SOG and TLD proteins, Cell 91: 417-426 (1997);
- TGFß-like growth factors The binding partner of the TGFß-like growth factors is decomposed by specific proteolysis.
- the PCP may also have a TGFß agonistic activity. Therefore, the PCP can be assigned a crucial role in fibrogenesis.
- the PCP activity is due to splicing variants of the BMP-I gene [cf. Kessler E, Takahara K, Biniaminow L, Brusel M, Greenspan DS: Bone morphogenetic protein-1: The type I procollagen C-proteinase, Science 271: 360-362 (1996)); Reddi AH:
- BMP-1 Resurrection as procollagen C proteinase. Science 217: 463 (1996); Li SW, Sieron AL, Fertala A, Hojima Y, Arnold WV, Prockop DJ: The C-proteinase that processes procollagens to fibrillar collagens is identical to the protein previosly identified as bone-morphogenetic protein- 1. Proc. Natl. Acad. Be. USA 93: 5127-5130 (1996)]. So far it has been ensured that the splice variants BMP I-I and BMP I-III
- PCP belongs to the family of astacin proteases.
- the crystal structure of Astacin is known in detail.
- R 1 represents hydrogen or methyl
- Physiologically acceptable salts are preferred in the context of the invention.
- Physiologically acceptable salts are generally salts of the compounds according to the invention with inorganic or organic acids. Salts with inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid, or salts with organic carboxylic or sulfonic acids, such as acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, are preferred. acid, or methanesulfonic acid, ethanesulfonic acid, phenylsulfonic acid, toluenesulfonic acid or naphthalenedisulfonic acid.
- the compounds according to the invention can exist in stereoisomeric forms which either behave like image and mirror image (enantiomers) or do not behave like image and mirror image (diastereomers).
- the invention relates to both the antipodes and the racemic forms as well as the diastereomer mixtures.
- the compounds of the general formula (I) can exist in all enantiomeric and diastereomeric forms.
- Preferred isomers are those in which the parts of the molecule formed from proline, lysine and leucine have the L configuration, as well as their salts and prodrugs.
- Phosphinate peptide analogs of the general formula (I) with the configuration shown are particularly preferred
- R 1 represents hydrogen or methyl
- the compound of the general formula (Ib) is very particularly preferred
- the compounds of the general formula (I) are known and can in principle be prepared from corresponding phosphinate compounds by customary methods of peptide synthesis [cf. see Yiotakis A, Vassilio S, Jiracek J, Dive V: Protection of the Hydroxyphosphinyl Function of Phosphinic Dipeptides by Adamantyl. Application to the Solid-Phase Synthesis of Phosphinic Peptides, J. Org. Chem. 61: 6601-6605 (1996); Campagne JM, Coste J, Guillou L, Heitz A, Jouin P: Solid phase synthesis of phosphinic peptides, Tetrahedron Lett. 34: 4181-4184
- Meprin I ⁇ IG-Q
- This loop forms the essential part of the Sl 'binding pocket of the astacin-like proteases.
- astacin and meprin lies the key to the different substrate and inhibitor specificity of both enzymes.
- Meprin and Astacin differ very clearly in the Sl 'pocket.
- the PCP also has two proline residues and one lysine residue in this region. How through
- the compounds according to the invention are distinguished by a very high potency in inhibiting PCP.
- the compounds according to the invention are therefore suitable for the treatment of liver fibrosis of any genesis and fibrosis with a different organ manifestation.
- liver fibrosis of different origins, such as e.g. alcoholic cirrhosis of the liver, biliary cirrhosis, hepatitis viral or other genesis, idiopathic interstitial fibrosis, idiopathic pulmonary fibrosis, acute pulmonary
- Fibrosis the acute respiratory distress syndrome (ARDS), perimuscular fibro- sen, pericentral fibrosis, dermatofibromas, renal fibrosis, diabetic nephropathy, glomerulonephritis, systemic or local scleroderma, keloids, hypertrophic scarring, joint adhesions, arthrosis, myelofibrosis, scarring of the cornea, muscular fibrosis, the cystic fibrosis, the cystic fibrosis, the cystic fibrosis muscular dystrophy, esophageal stricture, 'Ormond's disease,
- the invention also includes fibrotic diseases which are initiated or caused by surgical scar revisions, plastic surgery, glaucoma, cataract fibrosis, scarring of the cornea, the so-called "graft versus host disease", surgical interventions on tendons, nerve pinching syndromes, the Dupuytren's contracture , Adhesions due to gynecological interventions, pelvic adhesions, peridural fibrosis, diseases of the thyroid or parathyroid glands, due to metastatic bone infestation, multiple myeloma or restenosis.
- a synthetic decapeptide substrate with the sequence was used to detect the PCP activity
- This peptide frequency corresponds to the region in the
- Procollagen ⁇ 2 (I) which is cleaved by PCP.
- the fission sequence is known to biochemical experts [cf. Lee ST, Kessler E, Greenspan DS: Analysis of site-directed mutations in human pro- ⁇ 2 (I) collagen which block cleavage by the C-proteinase, J. Biol. Chem. 265: 21992-21996 (1990)] as well the procedure of the dequench test [cf. Matayoshi ED, Wang GT, Krafft GA, Erickson J: Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer, Science 247: 954-958 (1989)].
- the concentration of the synthetic peptide was 5.6 ⁇ M, the final buffer conditions were: 50 mM Tris pH 7.5, 150 mM NaCl and 0.005% Br ' ij35.
- the kinetic test was carried out as described below: The fluorescent substrate was dissolved in 90 ⁇ l reaction buffer. The kinetics of substrate turnover by PCP was detected in duplicate by fluorescence measurement (Ex. 355 nm / Em. 538 nm) between 0 to 120 min. The reaction was through
- the relative substrate turnover in% of the total amount was calculated from:
- Ft is the relative fluorescence after a time interval t under incubation with PCP.
- Ft is the corresponding relative fluorescence after the time interval t without PCP addition
- Ftotal is the fluorescence after total hydrolysis by adding proteinase K
- Fini is the initial relative fluorescence before the start of the reaction by adding proteinase K.
- the PCP activity used was typically adjusted so that approximately 20% of the substrate was reacted with the inhibited enzyme within the measurement period.
- Figure 1 is a typical reaction kinetics (% conversion) 'with the addition of
- Phosphinate inhibitors Z- PKF (PC) APL-O-Me Phosphinate inhibitors Z- PKF (PC) APL-O-Me.
- Figure 2 shows the concentration-activity relationship of a phosphinate inhibitor.
- Meprin is an enzyme from the family of astacin proteases that occurs in humans (Stöcker W, Gomis-Rüth FX, Bode W, Zwilling R: Implications of the three-dimensional structure of astacin for the structure and function of the astacin family of zinc- endopeptidases, Eur. J. Biochem. 214: 215-231 (1993)).
- the __- meprine activity test was carried out completely analogously to the in vitro assay for measuring the PCP activity. Instead of the recombinant PCP, human meprin was used, which also converts the fluorescence-labeled decapeptide.
- Figure 3 shows the specificity of the highly effective phosphinate peptide analog Z - PKF (PC) APL - O-Me for PCP. Even at concentrations up to 100 nM (dose-dependent), Meprin is only insignificantly inhibited during the conversion of the fluorescence-labeled peptide. Demonstration of biological effectiveness
- liver fibrosis by bile duct ligation [cf. Kountouras J, Billing B, Scheuer P: Prolonged bile obstruction: a new experimental model for cirrhosis in the rat, Br. J. Exp. Pathol. 1984; 65: 305-311 (1984)] or the liver fibrosis induced by heterologous serum [cf. Bhunchet E, Wake K .: Suppression of experimental hepatic fibrosis by administration of vitamin A, Lab. Invest. 1985; 52: 182-194 (1985)] can be used.
- Other animal models with liver fibrosis can also be used to demonstrate the antifibrotic effect.
- animal models can also be used for other fibrosis mam stations, for example in the heart, kidneys, lungs, skin or other organs.
- the reduction in collagen deposition can be determined, for example, by determining the hydroxyproline content [cf. Gerling B, Becker M, Waldschmidt J, Rehmann M, Schuppan D .: Elevated serum amino terminal procollagen type-III-peptide parallels collagen accumulation in rats with secondary biliary fibrosis, Hepatology 1996; 25: 79-84 (1996)] of the fibrotic organs or by quantitative morphometry [cf.
- Figure 1 shows the substrate turnover of the DABCYL-EDANS decapeptide by recombinant PCP as a function of time. The enzyme activity is almost completely inhibited in the presence of 100 nM inhibitor.
- Figure 2 shows the concentration-activity relationship of the phosphinate inhibitor
- Figure 3 shows the specificity of the highly effective phosphinate peptide analog Z - PKF (PC) APL - O-Me for PCP. Even at concentrations up to 100 nM (dose-dependent), Meprin is only insignificant in the implementation of the fluorescence-labeled
- the present invention also includes pharmaceutical preparations which, in addition to inert, non-toxic, pharmaceutically suitable auxiliaries and excipients, contain one or more compounds of the general formula (I) or which consist of one or more active compounds of the formulas (I), and processes for the preparation of these preparations.
- the active compounds of the formulas (I) should be present in these preparations in a concentration of 0.1 to 99.5% by weight, preferably 0.5 to 95% by weight, of the total mixture.
- the pharmaceutical preparations can also contain other pharmaceutical active ingredients.
- the pharmaceutical preparations listed above can be prepared in a customary manner by known methods, for example using the excipient or excipients.
- the active compound (s) in a total amount of about 0.01 to about 100 mg / kg, preferably in total amounts of about 1 mg / kg to 50 mg / kg body weight per 24 hours , if necessary in the form of several single doses, to achieve the desired result.
- Example la The protected amine derivative from Example la is dissolved in ethanol (approx. 0.05 mol / 1) and a catalyst (10% palladium on carbon) is added under argon. The suspension is approx. 2 at room temperature under H 2 atmosphere (normal pressure)
- Example lc The protected amine derivative from Example lc is dissolved in ethanol (approx. 0.05 mol / 1) and a catalyst (10% palladium on carbon) is added under argon. The suspension is approx. 2 at room temperature under H 2 atmosphere (normal pressure)
- Example le (1 R) - 1 - ( ⁇ (2S) -2- amino-6 - [(tert-butoxycarbonyl) amino] hexanoyl ⁇ - amino) -2-phenylethy 1 ⁇ 3 - [(2S) - 2- ( ⁇ [(15) - 1 - (methoxycarbony l) -3 - methylbutyl] amino ⁇ carbony l) tetrahydro-1 H-pyrrole-1-yl] -2-methyl-3-oxopropyl ⁇ phosphinic acid
- 0.3 ml of trifluoroacetic acid is added dropwise to 24.50 mg (0.03 mmol) of the compound from Example le in an ice-cooled mixture of 0.3 ml of methylene chloride and 0.03 ml of water. The cooling is removed and the mixture is stirred at room temperature for two hours before being concentrated in vacuo and dried thoroughly in a high vacuum.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99969897A EP1124845A2 (de) | 1998-10-30 | 1999-10-28 | Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungen |
CA002348934A CA2348934A1 (en) | 1998-10-30 | 1999-10-28 | Phosphinate peptide analogs for the treatment of fibrotic disorders |
AU31481/00A AU3148100A (en) | 1998-10-30 | 1999-10-28 | Phosphinate peptide analogs for the treatment of fibrotic disorders |
US09/830,741 US6750202B1 (en) | 1998-10-30 | 1999-10-28 | Phosphinate peptide analogs for the treatment of fibrotic disorders |
JP2000580606A JP2002529403A (ja) | 1998-10-30 | 1999-10-28 | 線維性疾患の処置のためのホスフィネートペプチド類縁体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19850072A DE19850072A1 (de) | 1998-10-30 | 1998-10-30 | Phosphinat-Peptidanaloga zur Behandlung von fibrotischen Erkrankungen |
DE19850072.6 | 1998-10-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000027377A2 true WO2000027377A2 (de) | 2000-05-18 |
WO2000027377A3 WO2000027377A3 (de) | 2000-11-16 |
Family
ID=7886165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/008181 WO2000027377A2 (de) | 1998-10-30 | 1999-10-28 | Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungen |
Country Status (7)
Country | Link |
---|---|
US (1) | US6750202B1 (de) |
EP (1) | EP1124845A2 (de) |
JP (1) | JP2002529403A (de) |
AU (1) | AU3148100A (de) |
CA (1) | CA2348934A1 (de) |
DE (1) | DE19850072A1 (de) |
WO (1) | WO2000027377A2 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002036154A2 (de) * | 2000-10-31 | 2002-05-10 | Burchardt Elmar R | Procollagen (iii)-propeptide und verwandte substanzen zur behandlung von fibrotischen erkrankungen |
WO2015104684A1 (en) * | 2014-01-10 | 2015-07-16 | Glaxosmithkline Intellectual Property (No.2) Limited | Hydroxy formamide derivatives and their use |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10134243A1 (de) * | 2001-07-14 | 2003-03-27 | Burchardt Elmar Reinhold | Phosphimat-Peptidanalyse zur Behandlung von fibrotischen Erkrankungen |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998008853A1 (en) * | 1996-08-28 | 1998-03-05 | The Procter & Gamble Company | Phosphinic acid amides as matrix metalloprotease inhibitors |
EP0854191A2 (de) * | 1997-01-02 | 1998-07-22 | Smithkline Beecham Corporation | Human cardiac/gehirn tolloid-ähnliches Protein |
-
1998
- 1998-10-30 DE DE19850072A patent/DE19850072A1/de not_active Withdrawn
-
1999
- 1999-10-28 EP EP99969897A patent/EP1124845A2/de not_active Withdrawn
- 1999-10-28 AU AU31481/00A patent/AU3148100A/en not_active Abandoned
- 1999-10-28 JP JP2000580606A patent/JP2002529403A/ja active Pending
- 1999-10-28 WO PCT/EP1999/008181 patent/WO2000027377A2/de active Application Filing
- 1999-10-28 US US09/830,741 patent/US6750202B1/en not_active Expired - Fee Related
- 1999-10-28 CA CA002348934A patent/CA2348934A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998008853A1 (en) * | 1996-08-28 | 1998-03-05 | The Procter & Gamble Company | Phosphinic acid amides as matrix metalloprotease inhibitors |
EP0854191A2 (de) * | 1997-01-02 | 1998-07-22 | Smithkline Beecham Corporation | Human cardiac/gehirn tolloid-ähnliches Protein |
Non-Patent Citations (3)
Title |
---|
BOND J S ET AL: "The astacin family of metalloendopeptidases" PROTEIN SCIENCE,GB,CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, Bd. 4, Nr. 7, Juli 1995 (1995-07), Seiten 1247-1261-1261, XP002111749 ISSN: 0961-8368 * |
FILE 'HOME' AT 17 10 49 ON 17 MAY 2000: "PROTECTION OF THE HYDROXYPHOSPHINYL FUNCTION OF PHOSPHINIC DIPEPTIDES BY ADAMANTYL APPLICATION TO THE SOLID-PHASE SYNTHESIS OF PHOSPHINIC PEPTIDES" J ORG CHEM (1996) 61(19) 6601-6605, XP002137994 * |
YIALLOUROS I ET AL.: "PHOSPHINIC PEPTIDES THE FIRST POTENT INHIBITORS OF ASTACIN BEHAVE AS EXTREMELY SLOW-BINDING INHIBITORS" BIOCHEMICAL JOURNAL (1998 APR 15) 331 ( PT 2) 375-9, XP002137993 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002036154A2 (de) * | 2000-10-31 | 2002-05-10 | Burchardt Elmar R | Procollagen (iii)-propeptide und verwandte substanzen zur behandlung von fibrotischen erkrankungen |
WO2002036154A3 (de) * | 2000-10-31 | 2003-01-30 | Elmar R Burchardt | Procollagen (iii)-propeptide und verwandte substanzen zur behandlung von fibrotischen erkrankungen |
WO2015104684A1 (en) * | 2014-01-10 | 2015-07-16 | Glaxosmithkline Intellectual Property (No.2) Limited | Hydroxy formamide derivatives and their use |
CN106103431A (zh) * | 2014-01-10 | 2016-11-09 | 葛兰素史密斯克莱知识产权(第2 号)有限公司 | 羟基甲酰胺衍生物及其用途 |
AU2015205370B2 (en) * | 2014-01-10 | 2017-11-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Hydroxy formamide derivatives and their use |
EA031654B1 (ru) * | 2014-01-10 | 2019-02-28 | Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед | Гидроксиформамидные производные и их применение |
CN106103431B (zh) * | 2014-01-10 | 2019-03-15 | 葛兰素史密斯克莱知识产权(第2 号)有限公司 | 羟基甲酰胺衍生物及其用途 |
CN109970797A (zh) * | 2014-01-10 | 2019-07-05 | 葛兰素史密斯克莱知识产权(第2 号)有限公司 | 羟基甲酰胺衍生物及其用途 |
US10450288B2 (en) | 2014-01-10 | 2019-10-22 | Glaxosmithkline Intellectual Property (No. 2) Limited | Hydroxy formamide derivatives and their use |
Also Published As
Publication number | Publication date |
---|---|
JP2002529403A (ja) | 2002-09-10 |
CA2348934A1 (en) | 2000-05-18 |
DE19850072A1 (de) | 2000-05-04 |
AU3148100A (en) | 2000-05-29 |
US6750202B1 (en) | 2004-06-15 |
WO2000027377A3 (de) | 2000-11-16 |
EP1124845A2 (de) | 2001-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69030315T2 (de) | Kleine zyklische inhibitoren der blutplättchenaggregation | |
JPH11511137A (ja) | コラーゲンの過剰生産に関係した疾患を治療するためのc−プロテイナーゼ阻害剤 | |
US5486623A (en) | Cysteine protease inhibitors containing heterocyclic leaving groups | |
DE69725354T2 (de) | Intermediate zur Herstellung von Thrombininhibitoren als Anticoagulantien | |
MXPA98001093A (en) | Inhibitors of proteinase c for the treatment of diseases related to the overproduction of colag | |
JPH09500087A (ja) | カルパイン活性の増大に関連した健康障害の抑制及び処置におけるカルパイン阻害剤の使用法 | |
US5672583A (en) | Carboxy-peptidyl derivatives as antidegenerative active agents | |
AU2007258387A2 (en) | Peptide fragments for inducing synthesis of extracellular matrix proteins | |
DE602004012777T2 (de) | 2-hydroxytetrahydrofuranderivate und ihre verwendung als arzneimittel | |
US5679700A (en) | Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents | |
EP1272458A1 (de) | Arginin-mimetika als faktor xa-inhibitoren | |
US5403952A (en) | Substituted cyclic derivatives as novel antidegenerative agents | |
CN104903314B (zh) | 1-[1-(苯甲酰基)-吡咯烷-2-羰基]-吡咯烷-2-甲腈衍生物 | |
CZ148599A3 (cs) | Substituovaný derivát kyseliny 4-bifenyl-4-hydroxymáselné jako základní látka inhibitorů metaloproteázy | |
DE69818698T2 (de) | Inhibitoren von metalloproteinasen, ihre therapeutische verwendung und verfahren zur herstellung der grundstoffe für ihre synthese | |
WO2000027377A2 (de) | Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungen | |
EP1483285B1 (de) | HEMMSTOFFE DES GERINNUNGSFAKTORS Xa, IHRE HERSTELLUNG UND VERWENDUNG | |
EP1455808B1 (de) | Phosphinat-peptidanaloga als inhibitoren der procollagen-c-proteinase (pcp) zur behandlung von fibrotischen erkrankungen | |
CA2224874A1 (en) | Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors | |
US6090785A (en) | Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents | |
DE69908756T2 (de) | Matrix-metalloproteinase-inhibitoren | |
WO1994027958A1 (de) | 4-amidinophenylsulfonamide zur behandlung von thromboembolischen erkrankungen | |
DE60036087T2 (de) | Niedermolekulare peptidderivate als inhibitoren der laminin/nidogen wechselwirkung | |
JP2003502442A (ja) | セリンエラスターゼの活性を阻害する方法及び化合物 | |
FR2770844A1 (fr) | Inhibiteurs de toxines clostridiales et compositions pharmaceutiques les contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999969897 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2348934 Country of ref document: CA Ref country code: JP Ref document number: 2000 580606 Kind code of ref document: A Format of ref document f/p: F Ref country code: CA Ref document number: 2348934 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09830741 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999969897 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |